Skip to content
Screener

EyePoint, Inc. EYPT EPS (Diluted)

EPS (Diluted) at other companies

Merck & Co. logo
Merck & Co.MRK
-$0.54-131%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$12.23-4.5%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-$0.40-5.3%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
-$0.94+13.8%
Regenxbio logo
RegenxbioRGNX
$0.43+131%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
-$1.01-17.4%

Other financials

Income statement

See full
Revenue$507.0K-90.5%
Gross profit$9.8M-30.1%
Operating income-$97.4M-56.5%
Net income-$94.5M-59.0%

Balance sheet

See full
Cash & equivalents$110.5M+55.3%
Total debt$22.4M-5.7%
Total equity$166.4M-32.4%
Total assets$228.2M-24.2%

Cash flow

See full
Operating cash flow-$62.3M+0.4%
CapEx$1.2M-1.6%
Free cash flow-$63.5M+0.4%

Valuation

See full
Market cap$1.11B+51.9%
Enterprise value$1.02B+49.6%
P/S396.6×+383×

Profitability

See full
Operating margin-11,365.2%-11,754pp
Net margin-10,994.7%-11,355pp
FCF margin-9,726.7%-10,132pp

Returns & leverage

See full
Return on equity-148.7%-13,871pp
Debt / equity0.1×0.0×
Current ratio4.5×-3.5×

Where this comes from

Reported directly by EyePoint, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: EyePoint, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335037
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Provision for income taxes(93)50(93)
Net loss$(94,470)$(59,426)$(179,302)$(104,621)
Net loss per share:
Basic and diluted$(1.09)$(0.85)$(2.08)$(1.50)
Weighted average common shares outstanding:
Basic and diluted86,54369,92686,27269,847
Net loss$(94,470)$(59,426)$(179,302)$(104,621)
Other comprehensive income (loss):

Item 1. Unaudited Financial Statements

FAQ

What is EyePoint, Inc.'s EPS (diluted)?
EyePoint, Inc. (EYPT) reported EPS (diluted) of -$1.09 in Q2 2026.
How has EyePoint, Inc.'s EPS (diluted) changed year-over-year?
EyePoint, Inc.'s EPS (diluted) decreased by 28.2% year-over-year, from -$0.85 to -$1.09.
What is the long-term trend for EyePoint, Inc.'s EPS (diluted)?
Over 4 years (2021 to 2025), EyePoint, Inc.'s EPS (diluted) has grown at a 11.6% compound annual growth rate (CAGR), from -$2.04 to -$3.17.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about EyePoint, Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude